Adaptimmune
Home
Our Company
Overview
arrow_forward
Board of Directors
arrow_forward
Leadership Team
arrow_forward
Products
Pipeline
Overview
arrow_forward
Afami-cel
arrow_forward
Lete-cel
arrow_forward
Uza-cel
arrow_forward
Technology
Overview
arrow_forward
Manufacturing
arrow_forward
Publications
arrow_forward
Patients & Families
Overview
arrow_forward
Taking Part in Our Clinical Trials
arrow_forward
Videos
arrow_forward
Clinical Trials
Overview
arrow_forward
Expanded Access Policy
arrow_forward
Investors & Media
Overview
arrow_forward
News Center
arrow_forward
Financial Info and Governance
arrow_forward
Stock Data
arrow_forward
SEC Filings
arrow_forward
Contact
Careers
Overview
arrow_forward
US Careers
arrow_forward
UK Careers
arrow_forward
Search
All SEC Filings
Investors & Media
Investors & Media
Overview
News Center
Media Resources
Corporate Presentations
Press Releases
Publications
Events
Email Alerts
Financial Info and Governance
General Meeting (merger)
Company Information
Leadership Team
Financial Results
Income Statement
Balance Sheet
Cash Flow
Board of Directors
Board Committees
Governance Documents
Annual Shareholder Meeting
FAQ
Contacts
Adaptimmune Ltd Report
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
10-K
10-Q
10-Q/A
20-F
3
4
424B3
424B4
424B5
425
6-K
8-A12B
8-K
8-K/A
ARS
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DRS
DRS/A
DRSLTR
EFFECT
F-1
F-1/A
F-1MEF
F-6
F-6EF
NT 10-K
PRE 14A
S-3
S-3/A
S-3ASR
S-4
S-4/A
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Date
Form
Description
PDF
XBRL
Pages
04/06/23
UPLOAD
SEC-generated letter
Documents
TEXT-EXTRACT
1
04/05/23
S-4
Registration of securities issued in business combination transactions
Documents
EX-2.2
EX-23.1
EX-23.2
EX-99.1
EX-99.2
EX-FILING FEES
371
04/03/23
PRE 14A
Preliminary proxy statement not related to a contested matter or merger/acquisition
114
03/30/23
SC 13D/A
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
26
03/10/23
8-K
Current report filing
3
03/09/23
425
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
4
03/09/23
425
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
14
03/06/23
10-K
Annual report pursuant to Section 13 and 15(d)
Documents
EX-4.4
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
167
03/06/23
8-K
Current report filing
Documents
EX-10.1
EX-99.1
19
03/06/23
425
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Documents
EX-2.1
EX-10.1
EX-10.2
EX-99.1
EX-99.2
EX-99.3
EX-99.4
99
Previous
1…
7
8
9
10
11
12
13
14
15
16
…73
Next